
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)13091-5
10.1016/j.heliyon.2024.e37060
e37060
Review Article
Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment
Deng Yayuan a1
Shi Mengjia b1
Yi Lin a1
Naveed Khan Muhammad b
Xia Zhijia c
Li Xiaosong lixiaosong@cqmu.edu.cn
bd⁎
a The First College of Clinical Medicine, Chongqing Medical University, Chongqing, China
b Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China
c Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, 81377, Germany
d Western(Chongqing) Collaborative Innovation Center for Intelligent Diagnostics and Digital Medicine, Chongqing National Biomedicine Industry Park, No. 28 Gaoxin Avenue, High-tech Zone, Chongqing, 401329, China
⁎ Corresponding author. Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. lixiaosong@cqmu.edu.cn
1 These authors have contributed equally to this work.

30 8 2024
15 9 2024
30 8 2024
10 17 e3706029 2 2024
10 8 2024
27 8 2024
© 2024 The Authors. Published by Elsevier Ltd.
2024

https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing remarkable clinical outcomes for patients with various cancer types. However, only a subset of patients benefits from immunotherapeutic interventions due to the primary and acquired resistance to ICIs. Myeloid-derived suppressor cells (MDSCs) play a crucial role in creating an immunosuppressive tumor microenvironment (TME) and contribute to resistance to immunotherapy. V-domain Ig suppressor of T cell activation (VISTA), a negative immune checkpoint protein highly expressed on MDSCs, presents a promising target for overcoming resistance to current ICIs. This article provides an overview of the evidence supporting VISTA's role in regulating MDSCs in shaping the TME, thus offering insights into how to overcome immunotherapy resistance.

Keywords

VISTA
MDSC
Tumor microenvironment
ICIs
Immunotherapy resistance
==== Body
pmc1 Introduction

The advent of immunotherapies has revolutionized the approach to treating cancer by augmenting natural immune responses to tumors [1,2]. Among these therapies, immune-checkpoint blockade is particularly promising due to its remarkable long-term clinical outcomes in advanced-stage cancer patients [3]. Specifically, immune checkpoint inhibitors (ICIs) that target inhibitory immune-checkpoint receptors such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) have been approved by the Food and Drug Administration (FDA) for treating over nineteen cancer types and two tissue-agnostic conditions [4,5]. However, despite the considerable success of immune checkpoint therapy (ICT), some patients with various tumor types have not benefited from it and may have even experienced life-threatening side effects, known as immune-related adverse events (irAEs), such as cardiac toxicity and acute kidney injury [1,6]. The response to immune checkpoint blockade is influenced by the tumor microenvironment (TME), which often exhibits immune-based resistance [7]. Myeloid-derived suppressor cells (MDSCs) are a critical driver of the immunosuppressive microenvironment in TME and may contribute to primary and acquired resistance to ICIs [8]. MDSCs originate from immature myeloid progenitor cells (IMPs) in chronic pathological conditions like cancer and can suppress the function of T and natural killer cells that fight against tumors [9,10]. Therefore, current research aims to identify new immune checkpoint targets beyond PD-1 and CTLA-4 to overcome resistance [11].

VISTA, also known as PD-1 homolog (PD-1H), differentiation of embryonic stem cells 1 (Dies1), DD1a, Gi24, SISP1, B7-H5, and C10orf54, is an emerging immune checkpoint protein that promotes cancer progression by suppressing immune responses, thereby making VISTA a promising target for cancer immunotherapy [12,13]. Previous studies suggest that VISTA shares homology with members of the B7 family but displays unique biological properties. VISTA regulates both innate and adaptive immune responses and can serve as both a ligand and a receptor in intercellular communication, although its function remains to be fully elucidated [12,14]. VISTA is highly expressed in tumoral cells, lymphoid cells, and hematopoietic cells. VISTA overexpression has been observed in several tumor types, including small intestine cancer, stomach cancer, pancreatic cancer, sarcoma, and neuroendocrine tumors, all of which are more than the average proportion across all cancers [15]. Unlike other negative checkpoint regulators that are expressed on activated T cells, VISTA is expressed on naive T cells and helps maintain their quiescence and peripheral tolerance under steady-state conditions [16]. Notably, myeloid cells exhibit the highest levels of VISTA expression [17]. In fact, VISTA expression is tenfold higher in MDSCs in the TME compared to peripheral lymph nodes [18]. Based on this, several studies have suggested that VISTA may play a crucial role in regulating the MDSC population. However, few reviews have focused on this topic. To address this gap, this review synthesizes relevant studies exploring the relationship between VISTA and MDSCs and examines the potential of VISTA in modulating MDSCs.

2 The relationship between VISTA and MDSC

2.1 VISTA highly expressing on MDSC

Notably, the myeloid lineage exhibits the greatest levels of VISTA expression, which is primarily expressed within the hematopoietic compartment. The greatest amounts of VISTA protein expression have been observed in MDSCs [14,19]. In the peripheral blood of AML patients, Wang L et al. found that VISTA is strongly expressed on MDSCs [20]. Hypoxia and DNA methylation are two mechanisms that boost VISTA expression on MDSC. Low oxygen levels, or hypoxia, are a characteristic of solid tumors [21] and they cause the increase of VISTA on MDSCs in the TME [22]. The inadequate oxygenation in TME results in a hypoxic state that promotes tumor angiogenesis, tumor development, and spread [23]. This hypoxic state is brought on by the fast growth of tumor cells and the twisted blood vessels. One way that hypoxia invades the TME is by increasing the activity of CXC family members and their corresponding CXC receptors (CXC-R) [24]. On the other hand, in the presence of hypoxia, HIF-1 attaches to conserved hypoxia-responsive regions in the VISTA promoter, upregulating VISTA on MDSCs in the TME [22,25]. The primary hypoxic regulator is HIF-1. Prolyl hydroxylases (PHDs) cannot hydroxylate two proline residues (Proline-402 and Proline-564) in the HIF-1 component in low oxygen environments, and as a result, von Hippel-Lindau protein (pVHL) cannot ubiquitinate its target, stabilizing HIF-1 [25]. Since the downstream gene expression switches cellular metabolism from oxidative phosphorylation to glycolysis, stabilizing (HIF-1) is essential for the adaptive response to hypoxia-induced oxidative stress [26]. Deng et al. discovered using flow analysis that hypoxic (pimo+) CD11b+ myeloid cells expressed significantly more VISTA than non-hypoxic cells, and that VISTA was expressed at greater levels on CD11bhighGr1+ MDSCs (pimo-). Additionally, under normoxic circumstances, CD11b+myeloid cells still expressed VISTA mRNA and protein in particular HIF-1 knockdown hPBMCs. Hypoxic antibody targeting or VISTA genetic deletion alleviated MDSC-mediated T-cell repression [22].

DNA methylation is a mediator of VISTA transcriptional control in MDSCs [27]. Through DNA methylation, histone post-translational alterations, and non-coding microRNAs (miRNAs), epigenetics alters phenotype that is not based on DNA structure [28,29]. The role of MDSC is altered epigenetically, which changes its features and reframes the microenvironment to inhibit tumor development and metastasis [30]. DNA methyltransferases (DNMTs) catalyze DNA methylation, and the two DNMT families, DNMT3 and DNMT1, are responsible for methylation establishment and maintenance, respectively [31]. The ten-eleven translocation (TET) enzymes, which function as 5-methylcytosine oxidases, can reverse locus-specific methylation [32]. In CD33+HLA-DR- myeloid cells, Saleh et al. discovered that DNMT3a is downregulated while TET enzymes are upregulated. This finding raises the possibility that TET-mediated active demethylation is what is responsible for the increase of genes in CD33+HLA-DR-MDSCs cells. Additionally, it has been discovered that VISTA mRNA expression levels are similarly upregulated in both CD33+HLA-DR- and CD33+HLA-DR+ MDSC subpopulations, whereas PD-L1, MMP9, and TIM-3 mRNA expression levels are significantly upregulated in the former compared to the latter, which is linked to CpG promoter unmethylation [27].

2.2 The structure of VISTA

The Vsir gene in rodents encodes the protein VISTA, which is highly conserved between species [33]. The mouse VISTA gene, which has 930 base pairs and can be transcribed into a type I transmembrane protein with a length of 309 amino acids (aa), is found on the forward strand of chromosome 10 (location 10qB4) [34]. There is 76 % similarity between a single extracellular Ig-V domain with 136 amino acids and a 23 amino acid stalk section and the human protein. Human VISTA and the transmembrane region, which has 21 amino acids and a cytoplasmic tail with 97 amino acids, are 90.6 % identical [34]. The human VISTA gene, like its mouse counterpart, produces a type I transmembrane protein. Human VISTA protein contains a 130-aa extracellular IgV domain, a 33-aa stalk region, a 32-aa signal peptide, a 20-aa transmembrane domain, and a lengthy 96-aa cytoplasmic tail [35]. The H-, A-, G-, F-, C-, and C′-strands make up the front face of the overall framework of VISTA, while the A′-, B-, E−, D-, and C″-strands make up the rear face. Three disulfide links that include each of the six cysteine residues have been established in its ECD according to the VISTA sequence [36]. Although the conserved cytoplasmic tail of VISTA lacks the traditional ITIM/ITAM motif, it has been discovered to contain possible protein kinase C binding sites and a proline-rich motif that may serve as a substrate for interaction [19].

The B7 family member that is most closely related to PD-L1 in terms of development is VISTA [37]. Numerous obvious distinctive characteristics of the VISTA amino acid sequence set it apart from other CD28/B7 family members, according to bioinformatic study [38]. The addition of an extra "H" -strand gives VISTA a lengthier IgV-Like do-main in the length of 137 amino acids compared to other V-set Ig domains, which limits VISTA's orientation on the cell surface [38]. The presumed B and F segments of the VISTA IgV domain are connected by a canonical disulfide link [19]. Additionally, it stands out from other members of the family by having about 20 continuous amino acids in the C-C′ region, 30 intramolecular hydrogen bonding contacts, and a disulfide bond (C51/C113). In contrast, the loop that links the two beta strands in PD-L1 and other B7 family proteins is a much more compact four residues. Additionally, the expanded C-C′ loop's protrusion from the beta-sandwich core is probably stabilized by two non-canonical and conserved disulfide bonds, or the distinctive structures of the VISTA, which link residues C12/C146 and C51/C113, respectively. Additionally, the histidine concentration of VISTA is significantly higher, especially in the FG loop region [36,38]. Its extracellular domain (ECD) contains 8.6 % histidine; in comparison, all type 1 transmembrane ECDs have a mean histidine concentration of only 2.4 % [38]. These distinct histidine groups with open surfaces may be very important for T-cell inhibition [38].

In summary, VISTA exhibits a relationship with other members of the B7 family but also has noticeable differences.

2.3 Binding partners for VISTA

VISTA serves dual roles as both a protein and a receptor [115]. According to studies, VISTA functions as an agonist for both the T cells' VSIG-3 receptor and the PSGL-1 receptor on T cells (Fig. 1). Other possible ligands for VISTA include VSIG8, NSC622608, and Galectin 9 [[39], [40], [41], [42], [43]].Fig. 1 Main biding partners of the VISTA and the involved structures. VISTA interacts with VSIG3 at physiological pH, but acidic (pH∼6.0) tumor microenvironment (TME) facilitates VISTA-expressing cells binding to PSGL-1 on T cell. Both interactions curtail T cell activities. Both associations reduce the activity of T cells [46]. Both engage with VISTA in the F68 and K70 of the C strand, the R86 and Q95 of the C-C′ loop, and the F-G loop (H154) [47].

Fig. 1

VSIG3, also referred to as IGSF11, BT-IgSF, BTIGSF, CT119, and CXADRL1, is a 46 kDa protein with 431 amino acids that is a member of the immunoglobulin group [44]. In gastrointestinal malignancies, such as colorectal cancer, hepatocellular carcinoma, and gastric cancer, VSIG3 is heavily expressed. Through its association with VISTA, VSIG3 regulates immune cell activity and influences the anti-tumor immune response.

PSGL-1, a 120 kD transmembrane protein that is predominantly produced as a homodimer on lymphoid and myeloid cells, has long been researched as an adhesion molecule involved in immune cell trafficking and is acknowledged as a regulator of many aspects of immune reactions by myeloid cells [45]. It is conceivable that the PSGL-1/VISTA pathway may play a significant role in preventing T-cell activation in acidic circumstances.

Potentially pH-selective is VISTA [39]. At physiological pH, VISTA engages with VSIG3, but an acidic (pH 6.0) TME makes it easier for VISTA-expressing cells to attach to PSGL-1 on T cells. Both associations reduce the activity of T cells [39,40]. The pH of the tumor microenvironment can therefore likely be targeted in order to decrease the immunoinhibitory activity of the VISTA. In the research by Mehta et al. the binding preferences of VISTA for PSGL-1 and VSIG3 were contrasted. The putative binding affinity for PSGL-1 was 4 nM at pH 6.0, which is frequently found in the TME, while the affinity for VSIG3 was 80 nM. In contrast, VSIG3's binding propensity to 20 nM increased four-fold at pH 7.4 while no evident binding to PSGL-1 was found [46]. Both engage with VISTA in the F68 and K70 of the C strand, the R86 and Q95 of the C-C′ loop, and the F-G loop (H154). Likewise, the nonprotruding F-G loop's three histidine residues, H153, H154, and H155, are crucial for PSGL-1 attachment. The inhibiting function of VISTA in antigen-specific T-cell tests was also decreased by substituting alanines for the triple-histidine cluster [47]. Additionally, under acidic circumstances, the amino group on the extracellular domain of histidine-rich VISTA is protonated, enabling contact with negatively charged PSGL-1. Human CD4+ T cells cocultured with VISTA-expressing cells in vitro produce more IFN-γ, have NF-B phosphorylated, and are more likely to proliferate due to an acidic pH-selective VISTA mAb that inhibits the PSGL-1/VISTA interaction [39]. The research by Johnson et al. demonstrates how environment affects lymphocyte-myeloid communication. Lymphocytes and myeloid cells can be harmed by the acidic and anaerobic conditions present in solid tumors [48].

2.4 VISTA modulates MDSC-mediated immunosuppression

Cancer cell interactions with their surroundings are crucial for the survival and development of tumors. The extracellular matrix (ECM) and soluble components, such as immune cells, are included in the TME [49].

Within the TME, myeloid-derived suppressor cells (MDSCs) contribute to an immunosuppressive environment that aids tumor evasion, which is by increasing the expression of T cell immunoinhibitory receptors, secreting immunosuppressive cytokines like IL-10 and TGF-β, depleting essential amino acids for T-cell activity and proliferation, facilitating the development of tumor-specific Tregs, and encouraging the production of free radical like ROS (Fig. 2) [50]. Notably, the elevated expression of VISTA on MDSCs suggests that VISTA may directly control MDSCs' ability to inhibit T cells in hosts with tumors [51].Fig. 2 MDSCs create immunosuppressive TME and the TLR/MyD88 signaling on MDSC is downregulated by VISTA. MDSC primarily inhibits T cells by 1) increasing the expression of T cell immunoinhibitory receptors, 2) secreting immunosuppressive cytokines, 3) depriving T cells of critical amino acids for activity and proliferation, 4) gathering Tregs, and 5) enhancing the generation of free radical. The TLR/MyD88-mediated communication is downregulated by VISTA. After TLRs are activated, the MyD88/IRAK1/4 complex recruits and triggers TRAF6, which in turn stimulates the MAPK/AP-1, IKK/NF-B, and MAPK pathways.

Fig. 2

Hypoxia enhances the inhibitory function of MDSCs in addition to upregulating VISTA on MDSCs in the TME (Fig. 3) [22]. First, since VISTA acts as a negative checkpoint regulator (NCR) by providing co-inhibitory signals upon counter-receptor engagement to reduce T cell response, its upregulation can significantly increase MDSCs' capacity for immunosuppression [52]. Second, hypoxia is one of the processes that helps to create an acidic pH environment, along with oncogene activity, the Warburg effect, and the interaction between VISTA and its ligands or receptors that is pH-selective [47]. HIF-driven glycolytic enzymes like lactate dehydrogenase A (LDHA), glucokinase (GCK), pyruvate kinase M2 (PKM2), and phosphofructokinase 1 (PFK1) were discovered to have dramatically elevated levels in conjunction with the upregulated HIF-1 expression under hypoxic circumstances [53]. A substantial quantity of lactate is produced during glycolysis, which is aided by hypoxia, aggravating the already acidic (pH 6.5–6.7) milieu [23]. The extracellular pH is significantly lowered as a result of the metabolism of the growing tumor cell, which also generates a large number of acidic metabolites and reduces their clearance [54]. Otto Warburg was the first to show that, even under aerobic circumstances, proliferating cancer cells increased their glucose intake and generated lactate. In cancer cells, the Warburg effect lowers the amount of ATP and CO2 produced by the mitochondria, which encourages the development of an alkaline internal pH (pHi) and an acidic external pH [55]. TME immunosuppressive niches and probable VISTA activity areas are caused by an acidic pH [47]. At an acidic pH, but not a normal pH, VISTA expressed on cancer cells, MDSCs, or tumor-associated macrophages (TAMs) can attach to PSGL-1 on T cells [47]. In acidic circumstances, VISTA engages with PSGL-1 and sends a signal into the T cell that inhibits immune function [47].Fig. 3 VISTA regulates MDSC-mediated inhibition through various mechanisms. By increasing the expression of VISTA on MDSC, hypoxia improves the delivery of co-inhibitory signals to T cells. VISTA inhibits TLR-mediated communication and the development of the MDSC C5a receptor on cell surfaces. The MDSC-mediated suppression enhancement through ARG1 also involves VISTA.

Fig. 3

Inducing a more immunosuppressive phenotype in rodents through VISTA signaling on myeloid cells can prevent the myeloid differentiation primary response to Myeloid differentiation factor 88 (MyD88)-dependent Toll-like receptor (TLR) signaling and cytokine secretion (Fig. 3) [47]. TLRs are pattern recognition receptors (PRRs) that detect various molecular sequences linked with pathogens (PAMPs). Following the recognition of PAMPs, PRRs initiate intracellular signaling cascades that result in the increase of co-stimulatory molecules as well as the induction of inflammatory cytokines and chemokines [56]. TLRs thus play a crucial part in controlling the immunological and inflammatory responses of the organism. MyD88-dependent pathway (TLR2/4/5/7/8/9) [57]. In the MyD88-dependent pathway, TLRs associate with TIR domains of MyD88 and MyD88 adaptor-like (Mal), a bridging adaptor between MyD88 and TLRs, recruiting serine/threonine kinases IRAKs (interleukin-1 receptor-associated kinases) to stimulate the TRAF6/IKK complex and MAPKK, which result in activation of MAP kinases, NF-κB and AP-1 [58]. The interleukin-1 receptor-associated kinases (IRAKs) are recruited by TLRs in the MyD88-dependent pathway, where they associate with MyD88's TIR domains and MyD88 adaptor-like (Mal), a bridging adaptor between MyD88 and TLRs. This stimulation of the TRAF6/IKK complex and MAPKK leads to the activation of MAP kinases, NF-B, and AP-1. A classic example of a pro-inflammatory signaling system is the nuclear factor NF-B pathway [59]. Tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-12, IL-1, and adhesion molecules are just a few examples of the cytokines and chemokines that are activated by NF-B after it separates from IB and moves to the nucleus [58]. By encouraging TRAF6 protein breakdown and limiting the stimulation of the MAPKs/AP-1 and IKK/NF-B signaling pathways, VISTA inhibits TLR-mediated signaling (Fig. 2) [13]. Absence of VISTA increases TLR-mediated generation of reactive cytokines. The expression of numerous cytokines and chemokines, such as IL12, IL6, GM-CSF, IFN-, MIP-1, and MIP-1, is substantially enhanced when Vsir/macrophages are stimulated ex vivo with TLR agonists CpG (TLR9) and R848 (TLR7) [51]. Except for PMN-MDSCs, VISTA inhibition increased the secretion of immune-stimulatory cytokines like IL12p40 in M-MDSCs [51]. In reaction to anti-CD3 stimulation, the addition of HMBD-002, an anti-VISTA antibody that blocks the C-C′ loop region of VISTA, effectively reversed MDSC-mediated T cell suppression, as shown by the increased levels of IFN-γ [60]. In low pH circumstances that simulate the TME, the highly selective anti-VISTA antibody PMC-309 binds to MDSC cells' VISTA and boosts the release of IFN-γ, TNF-α, and IL-2 in Mixed Lymphocyte Reaction (MLR) conditions [61]. Similar functions are performed in reversing MDSC immunosuppression by KVA-12.1, a new totally human anti-VISTA antibody [62]. Major immune response regulator IFN-γ, opposes the production of suppressive cytokines (TGF-β, IL-10) and encourages the development of IL-12. Additionally, macrophages' tumorigenic M2-differentiation is suppressed by IFN-γ [63]. Additionally, TLR4, MD-2, and MyD88 were required for the S100A8 (2–89) peptide to induce cell motility. After five days of therapy with Eritoran, a TLR4/MD-2 complex blocker, the recruitment of tumor-infiltrating myeloid suppressor cells was decreased [64]. When compared to MyD88+/+ TRAMPTg ± mice, the prostates of MyD88−/− TRAMPTg ± mice had more CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs), according to an analysis of invasive immune groups [65]. The MyD88-NF-B signaling pathway's effect on MDSCs, however, is complicated. Prostaglandin E2 from tumors (PGE2) causes nuclear p50 NF-B buildup in M-MDSCs, shifting their response to IFN toward NO-mediated immunosuppression and lowering TNF production [66]. By triggering the JNK-AP1 and Jak2-IRF1 signaling pathways, IFN + LPS significantly increased the production of the iNOS protein [67]. The simultaneous stimulation of ARG and NOS in myeloid cells harboring the tumor can produce strong inhibiting signals that ultimately cause anti-gen-specific T lymphocytes to undergo apoptosis [68]. According to Hu et alstudy, .'s the formation of MDSC was inhibited by NF-B inhibitors, and the growth of MDSC was dependent on the MyD88-NF-B pathway [69]. According to Zhang et al. MDSCs migrate to the tumor location via the CXCL2/MIF-CXCR2 signaling pathway, which in turn triggers the KF-b and MyD88-dependent MAPK pathways in MDSCs. Following MyD88 reduction, CXCR2 expression and p65, ERK, and p38 activation were reduced [70].

Once compared to cells from WT mice, VISTA-KO mice's peripheral blood and bone marrow both contained M-MDSCs and PMN-MDSCs, which reliably displayed lower surface expression of the C5a receptor [71]. The complement system's C5a protein is one of over 30 others [72]. Complement can be activated by DAMPs in the setting of cancer treatment and function as an effector of antibody-mediated tumor cytotoxic reactions. Complement activation, however, also has the potential to change the TME towards a tumor-supportive environment depending on a number of variables, including the tumor's cellular origin, its innate ability to produce autologous complement proteins, the makeup of the tumor microenvironment, and the degree of complement activation [73]. By affecting vascularization, the buildup of aberrant immune cells, and the extracellular matrix proteins, complement activity may have an effect on the development of the pre-metastatic niche [74]. By luring PMN-MDSCs to the main tumor location via its standard receptor C5aR1, C5a inhibits the antitumor CD8+ T cell-mediated response [75]. In the PMN-MDSC subgroup, C5a caused an amoeboid-like migration marked by a decrease in the quantity and size of focal adhesions, a reconfiguration of the cytoskeleton, an upregulation of CD11b, and a drop in extracellular 1 and 3 interferons through clathrin-coated endocytosis [74]. In the PMN-MDSC subgroup, C5a caused an amoeboid-like migration marked by a decrease in the quantity and size of focal adhesions, a reconfiguration of the cytoskeleton, an upregulation of CD11b, and a drop in extracellular 1 and 3 interferons through clathrin-coated endocytosis [76]. When C5a is present, M-MDSCs produce more ROS, which cause oxidative stress, which inhibits T cell translation, prevents T cells from adhering to modified MHC, and causes peripheral CD8+ T cells to become antigen-specifically tolerant [77]. In conclusion, VISTA may influence MDSC inhibition via C5a.

VISTA enhances M-MDSCs ability to suppress T cell expansion by promoting STAT3 activation, which may induce ARG1, a key enzyme supporting polyamine biosynthesis, under normoxia and certain hypoxia conditions (Fig. 3) [78]. In order to deplete L-arginine required for T cell proliferation, MDSCs exhibit large amounts of ARG1 and iNOS. The two enzymes deplete L-arginine by converting it into L-ornithine, urea, and NO while catabolizing it as a substrate [79]. By inhibiting cyclin D3 and cyclin-dependent kinase 4 (CDK4), L-arginine deprivation stops the T cell cycle in the G0-G1phase [80] and lowers the transcript of the T cell antigen receptor zeta chain (CD3zeta) [81]. In the meantime, NO suppresses T cell function through a variety of mechanisms, including attenuating MHC class II molecule induction, reversibly blocking IL-2 receptor signaling, inhibiting JAK3 and STAT5 function in T cells, mediating T cell DNA damage, and encouraging the differentiation of highly suppressive Treg cells through a cGMP-dependent mechanism [[82], [83], [84], [85], [86]]. It is shown that overexpression of STAT3 mutants (STAT3Y705E and STAT3S727D) upregulated AGR1 expression in Vsir−/− MDSCs. Zhang et al. observed that phosphorylation of STAT3S727 mediated by ERK1/2 activation is inhibited VISTA deletion. In addition, to sustain their own biosynthesis, polyamines promoted CK2 activity, STAT3 activation, and ARG1 expression in a positive feedback loop. In both WT and Vsir−/− MDSCs, ARG1 expression was diminished by STAT3 inhibitor (Stattic) treatment and rescued by putrescine supplementation. Besides, VISTA established a transcriptomic program that augments cellular metabolism, proliferation, and immunosuppressive function of tumor-associated MDSCs. Gene set enrichment analysis (GSEA) revealed that arginine metabolism, glycolysis, lipid metabolism, serine synthesis and mitochondrial respiration are downregulated in Vsir−/− MDSCs, while antigen presentation (e.g., MHCII, Ciita, CD74, etc.) and inflammatory signaling (e.g., Ifi202b, Grap, the C1q family, the Fc receptor family, Mmp-family genes, etc.) genes are upregulated. The transcriptomic changes in Vsir−/− MDSCs may be the result of not only STAT3-dependent activities but also polyamines that may directly interact with DNA, transcription factors, and chromatin-remodeling proteins [78].

2.5 Anti-VISTA contributes to reducing MDSC in TME

Extensive research has validated that VISTA blockade contributes to reducing MDSCs (see Table 1) [22,51,60,87,88].Table 1 Targeting VISTA contributes to reducing MDSCs.

Table 1Treatment	Drug name	Tumor model	Predominant MDSC population	MDSC reduction	Publication year	Ref	
VISTA monoclonal antibody (mab)	13F3	Murine bladder tumor model MB49	PMN-MDSCs (Cd11b + Gr1hiLy6G + Ly6C−int)	No obvious reduction	2014	[87]	
13F3	Murine melanoma model B16OVA	M-MDSCs (Cd11b + Gr1intLy6G−Ly6Chi）	Obvious reduction	2014	[87]	
13F3	Murine melanoma model B16-BL6	MDSCs (CD11b+ CD11C−Gr1+)	Obvious reduction	2014	[87]	
HMBD-002	Murine colon cancer CT26 syngeneic CDX model	MDSCs (CD11b+Gr1+ MHCII−)	Obvious reduction	2022	[60]	
SG7	Murine breast cancer model 4T1	PMN-MDSCs (CD45+)	Obvious reduction	2020	[46]	
4M2-C12 IgG2a	Murine lymphoma model EL4	PMN-MDSC (CD45+CD11 b+Ly6G + Ly6Clo/)	Obvious reduction	2019	[88]	
4M2-C12 IgG2a	Murine colon cancer model CT26	PMN-MDSC (CD45+CD11 b+Ly6G + Ly6Clo/)	Obvious reduction	2019	[89]	
13F3	Murine oral squamous cell carcinomaora model 4MOSC1 and 4MOSC2	M-MDSCs
(CD11b+LY6G−LY6Chi)	Obvious reduction	2023	[90]	
Blocking VISTA together with TLR stimulation	VISTA-blocking mAb with TLR agonists CpG and R848	Murine melanoma mode lB16-BL6	M-MDSCs (CD11b+CD11C−LY6ChiLY6G−)	Both M-MDSCs and PMN-MDSCs (CD11b+CD11C−LY6Cint LY6G+) were reduced	2019	[51]	
VISTA-targeted NIR-PIT with anti-VISTA-IR700	Anti-VISTA-IR700 followed by NIR light irradiation	Murine colon cancer model MC38	M-MDSC (CD45+CD11b+ Ly6C+Ly6G−)	Both M-MDSCs and PMN-MDSCs (CD45+ CD11b+ Ly6C− Ly6G+) were reduced	2022	[88]	
Murine lewis lung carcinoma model LL2	M-MDSC (CD45+CD11b+ Ly6C+Ly6G−)	Both M-MDSCs and PMN-MDSCs (CD45+ CD11b+ Ly6C− Ly6G+) were reduced	2022	[88]	
A peptide vaccine and peptides derived from known tumor-associated antigens	TRP2 peptide	Murine melanoma model B16F10	M-MDSCs
（CD11b+ Ly6Chi Ly6G−）	Obvious reduction	2024	[78]	
Adpgk and Rpl18 peptide	Murine colon cancer model MC38	M-MDSCs (CD11b + Ly6ChiCD11cnegLy6Gneg)	Both M-MDSCs and PMN-MDSCs (CD11b + Ly6Clo CD11cnegLy6G+)were reduced	2024	[78]	
VS3 and DVS3-Pal	peptide VS3 and peptide DVS3-Pal	Murine colorectal tumor model CT26	PMN-MDSCs (Cd11b+Ly6G+Ly6C−int)	Obvious reduction	2023	[91]	

The bulk of the VISTA-targeted medications presently being tested in clinical and preclinical settings have demonstrated encouraging therapeutic effectiveness [92]. Current human mAbs targeting VISTA signaling pathway include but are not limited to, CI-8993 [93], KVA-12.1 [94], W0 180 [95], PMC-309 [96], SNS-101 [97], VS7 [98], VS147 [98], 4M2-C12 [89], and SG 7 [46].

Notably, the predominant MDSC subsets differ in murine tumor models which may lead to MDSC reduction discrepancies while targeting VISTA. In murine models, MDSCs were initially characterized as cells expressing both CD11b and Gr-1 markers. Gr-1 is a heterodimeric protein complex comprising subunits from the Ly6 family, and cells were further classified into M-MDSCs (Ly6C+) or PMN-MDSCs (Ly6G+) [99]. Subsequently, additional subpopulations of murine MDSCs have emerged, leading to the identification of additional cell-surface markers that define MDSCs. Currently, it is widely accepted that murine PMN-MDSCs are cells with neutrophil-like characteristics that express CD11b+Ly6+Ly6Clow, while M-MDSCs are mononuclear cells defined as CD11b + Ly6Glow/−Ly6C+ [100]. However, relying solely on phenotypic criteria is inadequate for MDSC identification. Advances in techniques have led to the investigation of numerous MDSC subpopulations beyond the two broad categories [[101], [102], [103]]. Identification of MDSC subsets is critical in clinical settings, particularly in cancer immunotherapy, as these subsets exhibit varying biological characteristics in terms of T cell activation and immunosuppression, and can offer insights into managing immunotherapy resistance [104,105].

Of note, the suppressive pathways of PMN-MDSCs and M-MDSCs are distinct. The PMN-MDSC subset produces elevated levels of ROS that are unstable and active momentarily; as a result, they primarily exert immunosuppressive function by closely contacting T cells, disrupting T cells' binding to antigen-specific peptide-major histocompatibility complex (pMHC), but leaving them with the ability to respond to nonspecific stimulation [13,106]. Alessio Ugolini et al. also noted that PMN-MDSCs prevented DCs from directly presenting antigens while blocking antigen cross-presentation by these cells. The transmission of lipids is linked to this impact, which doesn't necessitate direct cell-to-cell contact [107]. In contrast, M-MDSCs preferentially generate nitric oxide (NO) and immunosuppressive cytokines like IL-10 and TGF-β, but they produce relatively little ROS, which results in generalized T-cell inactivation [100,108]. They both induce ER stress, activate transcription 3 (STAT3) expression, and produce arginase 1 [108]. In hyperoxia, M-MDSCs can quickly differentiate into TAMs, suggesting that they may have stronger suppressive activity than PMN-MDSCs [109,110]. Furthermore, despite the fact that MDSCs build up in both tumor tissues and peripheral lymphoid organs in tumor-bearing hosts, the evidence strongly suggests that tumor-infiltrated MDSCs exhibit a stronger suppressive feature than peripheral MDSCs [[111], [112], [113]]. During the development of the tumor, PMN-MDSCs gradually took the place of PMNs in the mice's spleens. Only tumors, where they manifest in the very early phases of the illness, contain activated PMN-MDSCs [114].

Whether VISTA inhibitors will maximally stop both PMN-MDSCs and M-MDSCs, however, is not certain. In contrast to the B16OVA model, Le Mercier et al. found that VISTA mAb treatment did not change the MDSC population infiltrating the MB49 bladder tumors. According to additional research, the majority of the MDSC community in the MB49 model is granulocytic phenotype, whereas the majority of the MDSC population in the B16OVA model is monocytic phenotype [87]. However, in 4T1 tumors, which have been shown to have substantial and uniform infiltrates of PMN-MDSCs, the active Fc form of the anti-VISTA antibody SG7 reduced the proportion of PMN-MDSCs. The PMN-MDSCs growth in the CT26, B16-BL6, and EL4 mice is suppressed by another anti-VISTA antibody, 4M2-C12 [89]. Additionally, Xu et al. discovered that TLR stimulation or VISTA-blocking mAb did not work to restore CD8+ T cells' capacity to produce IFN after being blocked by PMN-MDSCs [51]. This suggests that VISTA may control subpopulation-specific variations in MDSC migration and immunosuppression capacity. While M-MDSC function was reliant on IFN-γ signaling and independent of ER stress, Tcyganov et al. found that PMN-MDSC suppressive activity in cancer was controlled by the IRE1 and ATF6 pathways of the ER stress response [115]. Without affecting the suppressive action of PMN-MDSCs in spleens or tumors, deletion of IFN-R2 in M-MDSCs significantly decreased the expression of Nos2 in spleens [115].

The attachment of VISTA to PSGL-1 at acidic TME is disrupted by VS7, VS147, and SNS-101, which are pH-dependent [89,97,98]. It is notable that W0180 was shown to block VISTA's ability to bind to PSGL-1 regardless of the pH circumstances examined [116]. The anti-VISTA antibody HMBD-002 is an unusual IgG4 isotype that primarily targets the C-C′ loop, which is extremely conserved across model species. Across the spectrum of physiologically important pHs, HMBD-002 effectively reversed MDSC-mediated T-cell suppression and blocks VISTA-VSIG3 interactions [60]. A humanized monoclonal IgG1 antibody called 4M2-C12 has been demonstrated to block PSGL-1 and VSIG3 binding to VISTA in a dose-dependent way [89]. Purported associations between PSGL-1 and VSIG3 proteins are allegedly blocked by SG7.

Poor pharmacokinetics profiles, ineffectual tumor penetration, and expensive manufacturing expenses are some drawbacks of VISTA mAbs. Then came the development of small-molecule VISTA inhibitors, which had shortened half-lives and encouraged tumor infiltration [92]. The dietary antagonist CA170, the first small drug-like molecule inhibitor, has been applied in a dose-dependent way. In numerous tumor models in vivo, CA170 demonstrates anti-tumor effects akin to those of anti-PD-1 or anti-VISTA antibodies. Currently, a Phase 1 open-label, multicenter dose-escalation study (NCT02812875) of CA-170 has been completed for treating advanced solid tumors and lymphomas [17]. In patients with mesothelioma, CA-170 has demonstrated excellent safety characteristics with low rates of drug-related, immune-related or serious adverse events after oral dosing in continuous 21-day cycles. Treatment-emergent adverse event include but are not limited to, nausea, decreased appetite, anemia. As for efficacy, 7 of 11 evaluable patients had a best response of stable disease [117]. Moreover, CI-8993 has completed a Phase I trial (NCT04475523) evaluating its safety and anti-cancer efficacy in individuals with relapsed/refractory solid tumors [118], in which one patient experienced dose-limiting side effects related to cytokine release syndrome [119]. Another ongoing study (NCT05864144), a phase 1/2 open-label, multi-center trial, aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 either alone or combined with cemiplimab in patients with advanced solid tumors [120]. AUPM 493 [121] and NSC622608 [122] are two other small-molecule VISTA inhibitors that have been created. VISTA-targeted near-infrared photoimmunotherapy (NIR-PIT) also reduced VISTA-expressing MDSCs in theTME of MC38-luc tumors in addition to anti-VISTA antibodies and small-molecule VISTA inhibitors [88].

The immunosuppressive ability of MDSC may be impaired by VISTA depletion in three ways: 1) by hindering the infiltration of immature myeloid progenitor cells; 2) by stopping MDSC recruitment; and 3) by lowering the number of MDSCs infiltrating the tumor.

Under physiological conditions, the differentiation of common myeloid progenitor (CMP) into neutrophils or monocytes, and subsequently into dendritic cells (DCs) and macrophages, is typical, while in cancer-induced myelopoiesis, it may lead to skewed differentiation into M-MDSCs and TAMs or PMN-MDSCs and tumor-associated neutrophils (TANs) (Fig. 4) [100]. A novel, multi-step approach has recently been put forth to clarify the creation and recruitment of MDSCs. This paradigm can be broken down into four steps: step I, which is myelopoiesis; step II, which is blood movement; step III, which is homing to the tumor site; and step IV, which is retention at the tumor site (Fig. 4) [123].Fig. 4 MDSCs distinction and enrollment. Four stages make up the novel MDSC development paradigm. The hematopoietic progenitor cell (HPC) develops into a common myeloid progenitor (CMP) and then a granulocyte-monocyte progenitor (GMP). During the first stage of amplified myelopoiesis, which takes place in the bone marrow and liver can differentiate into adult myeloid cells, such as neutrophils, monocytes, and dendritic cells (DC), and eventually into macrophages, during the process of classical myeloid cell activation. However, under conditions of long-term inflammation, GMP is pathologically activated and transforms into M-MDSC, which may transform into TAM, and PMN-MDSC, which may transform into TAN. In steps II and III, these myeloid cells move into the circulatory system, recruit to the tumor location, and stay there in steps IV.

Fig. 4

According to a research by Le Mercier et al. VISTA blockade decreased the tumor-infiltrating M-MDSCs in the B16 melanoma model without clearly deleting peripheral myeloid or T cell lineages [87]. This change indicates that VISTA mAb therapy may hinder the infiltration of immature myeloid progenitor cells, which may differentiate into MDSCs at the tumor site, to impair the recruitment of M-MDSCs into tumor issues, impairing the suppressive cellular signature of the TME [87]. The ability of VISTA inhibition to reduce the number of MDSCs in the tumor bed locally and increase the influx of tumor-specific effector T cells has been confirmed. This results in the development of an immune-stimulating TME and improved anti-tumor immunity [87,88].

3 Discussion

VISTA is an immune checkpoint protein with distinctive biological features and is shown to be another promising immune checkpoint treatment target. Beyond its role as a ligand or receptor that regulates naïve T cells, VISTA can also function as a soluble molecule released by human peripheral monocytes and Acute myeloid leukemia (AML) cells. This soluble form of VISTA may contribute to the impairment of immune cell cytotoxicity by enhancing the effects of galectin-9 and inhibiting granzyme B delivery [43,124]. Interestingly, VISTA seems to play a dual role in tumor development. While high VISTA expression is generally associated with poor prognosis in patients [125], it also has been found to correlate with improved survival in early-stage endometrial cancer and esophageal adenocarcinoma (EAC) patients [15,126]. The relevant mechanism may involve VISTA downregulating the anti-phagocytic signal SIRPα, which enhances the phagocytic capacity of M2 macrophages against cancer cells [127]. These conflicting findings highlight the necessity for further investigation into VISTA's complex role in TME. Moreover, although PSGL-1 and VSIG-3 have been confirmed as binding partners of VISTA, additional research is required to identify other potential counter-receptors.

MDSCs may play a role in predicting the immunosuppressive tumor milieu and regulating the outcomes of cancer treatment. In terms of cancer immunology, this heterogeneous population of myeloid cells exhibits fascinating biological characteristics and forms a complex network with the immune cells in the TME, for example, attracting Tregs, quickly differentiating into TAMs, and encouraging the differentiation of fibroblasts into cancer-associated fibroblasts (CAFs) [128].

The fact that VISTA is highly expressed on MDSCs casts light on its possible function as a regulator of MDSCs. Hypoxia and DNA methylation may help upregulate VISTA on MDSCs in the TME, which enhances VISTA association with its binding patterners in an acidic environment and results in the delivery of more co-inhibitory signals that suppress T cell response. Myeloid differentiation factor 88 (MyD88)-dependent Toll-like receptor (TLR) signaling on MDSCs is downregulated by VISTA, and VISTA inhibition greatly increases the production of TLR-mediated proinflammatory cytokines like IL-12, IL-6, GM-CSF, IFN-γ, MIP-1, and MIP-1. Additionally, VISTA-KO mice's MDSCs regularly displayed lower C5a receptor surface expression, which may increase the ability of MDSCs to inhibit antitumor immunity. To better understand the potential processes underlying this, more concrete proof is required.

Importantly, prior research has shown that VISTA-targeted therapies aid in decreasing MDSC infiltration in TME, which has paved the way for beating tolerance to current immune checkpoint drugs by targeting VISTA. Notably, there is ongoing debate over whether anti-VISTA drugs are able to suppress both PMN-MDSCs and M-MDSCs. There is an immediate need for more study to determine which MDSC subsets, if either, could be reduced by anti-VISTA treatment. The two major subpopulations of MDSC, PMN-MDSC and M-MDSC, may be regulated by VISTA in distinct ways.

The possible connections between VISTA and MDSCs are still being explored, and more research is needed to fully understand the precise methods VISTA uses to control MDSCs. Without a question, thorough research into the powerful immunotherapy target VISTA and one of the most popular immunosuppressive promoters, MDSC, will offer a way to combat immunotherapy resistance.

Funding & acknowledgment

This study was funded by the Innovation and Development Joint Fund of Chongqing Natural Science Foundation (grant number CSTB2023NSCQ-LZX0099 ), Chongqing Science and Health Joint Medical High-end Talent Project (2022GDRC012 ), Science and Technology Research Program of 10.13039/501100007957 Chongqing Municipal Education Commission (KJZD-K202100402 ), 10.13039/501100004374 CQMU Program for Youth Innovation in Future Medicine (W0073).

Ethics approval and consent to participate

Review and/or approval by an ethics committee are not needed for this study because this review does not involve clinical and basic experiments.

Data availability

This study is a review and the raw data are available in referenced studies.

CRediT authorship contribution statement

Yayuan Deng: Writing – review & editing, Writing – original draft, Data curation. Mengjia Shi: Writing – review & editing, Writing – original draft. Lin Yi: Writing – original draft, Methodology, Formal analysis. Muhammad Naveed Khan: Writing – review & editing, Investigation. Zhijia Xia: Writing – review & editing, Validation, Data curation. Xiaosong Li: Supervision, Resources, Funding acquisition, Conceptualization.

Declaration of competing interest

All the authors declare that they have no competing interests.
==== Refs
References

1 Binnewies M. Roberts E.W. Kersten K. Chan V. Fearon D.F. Merad M. Coussens L.M. Gabrilovich D.I. Ostrand-Rosenberg S. Hedrick C.C. Vonderheide R.H. Pittet M.J. Jain R.K. Zou W. Howcroft T.K. Woodhouse E.C. Weinberg R.A. Krummel M.F. Understanding the tumor immune microenvironment (TIME) for effective therapy Nat. Med. 24 2018 541 550 10.1038/s41591-018-0014-x 29686425
2 Riley RS June CH Langer R Mitchell MJ Delivery technologies for cancer immunotherapy Nat Rev Drug Discov 18 2019 175 196 10.1038/s41573-018-0006-z 30622344
3 Xu W. Hiếu T. Malarkannan S. Wang L. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation Cell. Mol. Immunol. 15 2018 438 446 10.1038/cmi.2017.148 29375120
4 O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16 (2019)151-167. doi: 10.1038/s41571-018-0142-8.
5 Twomey J.D. Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics AAPS J. 23 2021 39 10.1208/s12248-021-00574-0 33677681
6 Immune-related adverse events of checkpoint inhibitors - PubMed, (n.d.). https://pubmed.ncbi.nlm.nih.gov/32382051/(accessed October 26, 2022).
7 Vesely M.D. Zhang T. Chen L. Resistance mechanisms to anti-PD cancer immunotherapy Annu. Rev. Immunol. 40 2022 45 74 10.1146/annurev-immunol-070621-030155 35471840
8 Barrueto L. Caminero F. Cash L. Makris C. Lamichhane P. Deshmukh R.R. Resistance to checkpoint inhibition in cancer immunotherapy Translational Oncology 13 2020 100738 10.1016/j.tranon.2019.12.010
9 Gabrilovich D.I. Myeloid-derived suppressor cells Cancer Immunol. Res. 5 2017 3 8 10.1158/2326-6066.CIR-16-0297 28052991
10 Najjar Y.G. Finke J.H. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer Front. Oncol. 3 2013 49 10.3389/fonc.2013.00049 23508517
11 Qin S. Xu L. Yi M. Yu S. Wu K. Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Mol. Cancer 18 2019 155 10.1186/s12943-019-1091-2 31690319
12 Hosseinkhani N. Derakhshani A. Shadbad M.A. Argentiero A. Racanelli V. Kazemi T. Mokhtarzadeh A. Brunetti O. Silvestris N. Baradaran B. The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead Front. Immunol. 12 2021 676181 10.3389/fimmu.2021.676181
13 Yum J.-E.I. Hong Y.-K. Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby Front. Oncol. 11 2021 658488 10.3389/fonc.2021.658488
14 ElTanbouly M.A. Croteau W. Noelle R.J. Lines J.L. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity Semin. Immunol. 42 2019 101308 10.1016/j.smim.2019.101308
15 Loeser H Kraemer M Gebauer F Bruns C Schröder W Zander T Persa OD Alakus H Hoelscher A Buettner R Lohneis P Quaas A The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma Oncoimmunology 8 2019 e1581546 10.1080/2162402X.2019.1581546
16 ElTanbouly M.A. Zhao Y. Nowak E. Li J. Schaafsma E. Le Mercier I. Ceeraz S. Lines J.L. Peng C. Carriere C. Huang X. Day M. Koehn B. Lee S.W. Silva Morales M. Hogquist K.A. Jameson S.C. Mueller D. Rothstein J. Blazar B.R. Cheng C. Noelle R.J. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance Science 367 2020 eaay0524 10.1126/science.aay0524
17 Li K. Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy J. Drug Target. 27 2019 244 256 10.1080/1061186X.2018.1440400 29448849
18 Tagliamento M. Bironzo P. Novello S. New emerging targets in cancer immunotherapy: the role of VISTA ESMO Open 4 2019 e000683 10.1136/esmoopen-2020-000683
19 Huang X. Zhang X. Li E. Zhang G. Wang X. Tang T. Bai X. Liang T. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy J. Hematol. Oncol. 13 2020 83 10.1186/s13045-020-00917-y 32600443
20 Wang L. Jia B. Claxton D.F. Ehmann W.C. Rybka W.B. Mineishi S. Naik S. Khawaja M.R. Sivik J. Han J. Hohl R.J. Zheng H. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML OncoImmunology 7 2018 e1469594 10.1080/2162402X.2018.1469594
21 Bao M.H.-R. Wong C.C.-L. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer Cells 10 2021 1715 10.3390/cells10071715 34359884
22 Deng J. Li J. Sarde A. Lines J.L. Lee Y.-C. Qian D.C. Pechenick D.A. Manivanh R. Le Mercier I. Lowrey C.H. Varn F.S. Cheng C. Leib D.A. Noelle R.J. Mabaera R. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment Cancer Immunol. Res. 7 2019 1079 1090 10.1158/2326-6066.CIR-18-0507 31088847
23 Yang M. Li J. Gu P. Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment Bioact. Mater. 6 2020 1973 1987 10.1016/j.bioactmat.2020.12.010 33426371
24 Korbecki J. Kojder K. Kapczuk P. Kupnicka P. Gawrońska-Szklarz B. Gutowska I. Chlubek D. Baranowska-Bosiacka I. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature Int. J. Mol. Sci. 22 2021 E843 10.3390/ijms22020843
25 Tirpe A.A. Gulei D. Ciortea S.M. Crivii C. Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes Int. J. Mol. Sci. 20 2019 6140 10.3390/ijms20246140 31817513
26 Sulkshane P. Ram J. Thakur A. Reis N. Kleifeld O. Glickman M.H. Ubiquitination and receptor-mediated mitophagy converge to eliminate oxidation-damaged mitochondria during hypoxia Redox Biol. 45 2021 102047 10.1016/j.redox.2021.102047
27 Saleh R. Toor S.M. Taha R.Z. Al-Ali D. Sasidharan Nair V. Elkord E. DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-β genes in HLA-DR – myeloid cells, compared with HLA-DR + antigen-presenting cells Epigenetics 15 2020 1275 1288 10.1080/15592294.2020.1767373 32419601
28 Harvey Z.H. Chen Y. Jarosz D.F. Protein-based inheritance: epigenetics beyond the chromosome Mol Cell 69 2018 195 202 10.1016/j.molcel.2017.10.030 29153393
29 Feng J.X. Riddle N.C. Epigenetics and genome stability Mamm. Genome 31 2020 181 195 10.1007/s00335-020-09836-2 32296924
30 Zhang C. Wang S. Liu Y. Yang C. Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer Oncotarget 7 2016 57452 57463 10.18632/oncotarget.10767 27458169
31 Chen Z. Zhang Y. Role of mammalian DNA methyltransferases in development Annu. Rev. Biochem. 89 2020 135 158 10.1146/annurev-biochem-103019-102815 31815535
32 Rasmussen K.D. Helin K. Role of TET enzymes in DNA methylation, development, and cancer Genes Dev. 30 2016 733 750 10.1101/gad.276568.115 27036965
33 Flajnik M.F. Tlapakova T. Criscitiello M.F. Krylov V. Ohta Y. Evolution of the B7 family: Co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC Immunogenetics 64 2012 571 590 10.1007/s00251-012-0616-2 22488247
34 D.B. Flies, S. Wang, H. Xu, L. Chen, Cutting edge: a monoclonal antibody speciﬁc for the programmed death-1 homolog prevents graft-versus-host disease in Mouse Models, (n.d.) 6.
35 Lines J.L. Pantazi E. Mak J. Sempere L.F. Wang L. O'Connell S. Ceeraz S. Suriawinata A.A. Yan S. Ernstoff M.S. Noelle R. VISTA is an immune checkpoint molecule for human T cells Cancer Res. 74 2014 1924 1932 10.1158/0008-5472.CAN-13-1504 24691993
36 Mehta N. Maddineni S. Mathews I.I. Andres Parra Sperberg R. Huang P.-S. Cochran J.R. Structure and functional binding epitope of V-domain Ig suppressor of T cell activation Cell Rep. 28 2019 2509 2516.e5 10.1016/j.celrep.2019.07.073 31484064
37 Wang L. Rubinstein R. Lines J.L. Wasiuk A. Ahonen C. Guo Y. Lu L.-F. Gondek D. Wang Y. Fava R.A. Fiser A. Almo S. Noelle R.J. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses J. Exp. Med. 208 2011 577 592 10.1084/jem.20100619 21383057
38 Slater B.T. Han X. Chen L. Xiong Y. Structural insight into T cell coinhibition by PD-1H (VISTA) Proc. Natl. Acad. Sci. U.S.A. 117 2020 1648 1657 10.1073/pnas.1908711117 31919279
39 Johnston R.J. Su L.J. Pinckney J. Critton D. Boyer E. Krishnakumar A. Corbett M. Rankin A.L. Dibella R. Campbell L. Martin G.H. Lemar H. Cayton T. Huang R.Y.-C. Deng X. Nayeem A. Chen H. Ergel B. Rizzo J.M. Yamniuk A.P. Dutta S. Ngo J. Shorts A.O. Ramakrishnan R. Kozhich A. Holloway J. Fang H. Wang Y.-K. Yang Z. Thiam K. Rakestraw G. Rajpal A. Sheppard P. Quigley M. Bahjat K.S. Korman A.J. VISTA is an acidic pH-selective ligand for PSGL-1 Nature 574 2019 565 570 10.1038/s41586-019-1674-5 31645726
40 Wang J. Wu G. Manick B. Hernandez V. Renelt M. Erickson C. Guan J. Singh R. Rollins S. Solorz A. Bi M. Li J. Grabowski D. Dirkx J. Tracy C. Stuart T. Ellinghuysen C. Desmond D. Foster C. Kalabokis V. VSIG-3 as a ligand of VISTA inhibits human T-cell function Immunology 156 2019 74 85 10.1111/imm.13001 30220083
41 Chen W. Qie C. Hu X. Wang L. Jiang J. Liu W. Liu J. A small molecule inhibitor of VSIG-8 prevents its binding to VISTA Invest. N. Drugs 40 2022 690 699 10.1007/s10637-022-01244-4
42 Gabr M.T. Gambhir S.S. Discovery and optimization of small-molecule ligands for V-domain Ig suppressor of T-cell activation (VISTA) J. Am. Chem. Soc. 142 2020 16194 16198 10.1021/jacs.0c07276 32894020
43 Yasinska I.M. Meyer N.H. Schlichtner S. Hussain R. Siligardi G. Casely-Hayford M. Fiedler W. Wellbrock J. Desmet C. Calzolai L. Varani L. Berger S.M. Raap U. Gibbs B.F. Fasler-Kan E. Sumbayev V.V. Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity Front. Immunol. 11 2020 580557 10.3389/fimmu.2020.580557
44 Tang X.-Y. Xiong Y.-L. Shi X.-G. Zhao Y.-B. Shi A.-P. Zheng K.-F. Liu Y.-J. Jiang T. Ma N. Zhao J.-B. IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy Biomark. Res. 10 2022 49 10.1186/s40364-022-00394-0 35831836
45 Tinoco R. Otero D.C. Takahashi A. Bradley L.M. PSGL-1: a new player in the immune checkpoint landscape Trends Immunol. 38 2017 323 335 10.1016/j.it.2017.02.002 28262471
46 Mehta N. Maddineni S. Kelly R.L. Lee R.B. Hunter S.A. Silberstein J.L. Parra Sperberg R.A. Miller C.L. Rabe A. Labanieh L. Cochran J.R. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA Sci. Rep. 10 2020 15171 10.1038/s41598-020-71519-4
47 Yuan L. Tatineni J. Mahoney K.M. Freeman G.J. VISTA: a mediator of quiescence and a promising target in cancer immunotherapy Trends Immunol. 42 2021 209 227 10.1016/j.it.2020.12.008 33495077
48 Gong T. Zhou R. Acidity changes immunology: a new VISTA pathway Nat. Immunol. 21 2020 9 11 10.1038/s41590-019-0562-3 31822868
49 Xiao Y. Yu D. Tumor microenvironment as a therapeutic target in cancer Pharmacol. Ther. 221 2021 107753 10.1016/j.pharmthera.2020.107753
50 Dysthe M. Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment Adv. Exp. Med. Biol. 1224 2020 117 140 10.1007/978-3-030-35723-8_8 32036608
51 Xu W. Dong J. Zheng Y. Zhou J. Yuan Y. Ta H.M. Miller H.E. Olson M. Rajasekaran K. Ernstoff M.S. Wang D. Malarkannan S. Wang L. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell–mediated inflammation and immunosuppression Cancer Immunol. Res. 7 2019 1497 1510 10.1158/2326-6066.CIR-18-0489 31340983
52 Nowak E.C. Lines J.L. Varn F.S. Deng J. Sarde A. Mabaera R. Kuta A. Le Mercier I. Cheng C. Noelle R.J. Immunoregulatory functions of VISTA Immunol. Rev. 276 2017 66 79 10.1111/imr.12525 28258694
53 Tang Y. Zhu J. Huang D. Hu X. Cai Y. Song X. Song Z. Hong C. Feng Z. Kang F. Mandibular osteotomy-induced hypoxia enhances osteoclast activation and acid secretion by increasing glycolysis J. Cell. Physiol. 234 2019 11165 11175 10.1002/jcp.27765 30548595
54 Thews O. Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia Cancer Metastasis Rev. 38 2019 113 129 10.1007/s10555-018-09777-y 30607627
55 Icard P Shulman S Farhat D Steyaert JM Alifano M Lincet H How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat 38 2018 1 11 10.1016/j.drup.2018.03.001 29857814
56 Kawai T, Akira S. TLR signaling. Semin Immunol.19 (2007) 24-32. doi: 10.1016/j.smim.2006.12.004.
57 Takeda K. Akira S. Toll-like receptors Curr. Protoc. Im. 109 2015 14.12.1 14.12.10 10.1002/0471142735.im1412s109
58 Guven Maiorov E. Keskin O. Gursoy A. Nussinov R. The structural network of inflammation and cancer: merits and challenges Semin. Cancer Biol. 23 2013 243 251 10.1016/j.semcancer.2013.05.003 23712403
59 Lawrence T. The nuclear factor NF-kappaB pathway in inflammation Cold Spring Harbor Perspect. Biol. 1 2009 a001651 10.1101/cshperspect.a001651
60 Thakkar D. Paliwal S. Dharmadhikari B. Guan S. Liu L. Kar S. Tulsian N.K. Gruber J.J. DiMascio L. Paszkiewicz K.H. Ingram P.J. D Boyd-Kirkup J. Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner J Immunother Cancer 10 2022 e003382 10.1136/jitc-2021-003382
61 Park C.H. Byun S.S. An J.Y. Ha S.H. Han H.R. Kang N.R. Park B.Y. Lee E.A. Park H.S. Yoo J.-S. Lee W.S. Abstract 1626: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC) Cancer Res. 81 2021 1626 10.1158/1538-7445.AM2021-1626
62 Thierry Guillaudeux Eric Tarcha Bader Robert Benjamin Dutzar Eyde Nathan Frazier Emily Lance Remington Cristina Loomis Kurt Lustig Yulia Ovechkina Peckham David Posakony Jeff Shaarwari Sridhar Xu Mei Shawn Iadonato; Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors Cancer Res. 81 2021 1637 10.1158/1538-7445 34003790
63 Burke J.D. Young H.A. IFN-Γ: a cytokine at the right time, is in the right place Semin. Immunol. 43 2019 101280 10.1016/j.smim.2019.05.002
64 Deguchi A. Tomita T. Ohto U. Takemura K. Kitao A. Akashi-Takamura S. Miyake K. Maru Y. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment Oncogene 35 2016 1445 1456 10.1038/onc.2015.211 26165843
65 Peek E.M. Song W. Zhang H. Huang J. Chin A.I. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes Prostate 75 2015 463 473 10.1002/pros.22932 25597486
66 Porta C. Consonni F.M. Morlacchi S. Sangaletti S. Bleve A. Totaro M.G. Larghi P. Rimoldi M. Tripodo C. Strauss L. Banfi S. Storto M. Pressiani T. Rimassa L. Tartari S. Ippolito A. Doni A. Soldà G. Duga S. Piccolo V. Ostuni R. Natoli G. Bronte V. Balzac F. Turco E. Hirsch E. Colombo M.P. Sica A. Tumor-derived prostaglandin E2 promotes p50 NF-κB-Dependent differentiation of monocytic MDSCs Cancer Res. 80 2020 2874 2888 10.1158/0008-5472.CAN-19-2843 32265223
67 Wu F. Tyml K. Wilson J.X. iNOS expression requires NADPH oxidase-dependent redox signaling in microvascular endothelial cells J. Cell. Physiol. 217 2008 207 214 10.1002/jcp.21495 18481258
68 Bronte V. Kasic T. Gri G. Gallana K. Borsellino G. Marigo I. Battistini L. Iafrate M. Prayer-Galetti T. Pagano F. Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers J. Exp. Med. 201 2005 1257 1268 10.1084/jem.20042028 15824085
69 Hu C.-E. Gan J. Zhang R.-D. Cheng Y.-R. Huang G.-J. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function Scand. J. Gastroenterol. 46 2011 156 164 10.3109/00365521.2010.516450 20822377
70 Zhang H. Ye Y.-L. Li M.-X. Ye S.-B. Huang W.-R. Cai T.-T. He J. Peng J.-Y. Duan T.-H. Cui J. Zhang X.-S. Zhou F.-J. Wang R.-F. Li J. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer Oncogene 36 2017 2095 2104 10.1038/onc.2016.367 27721403
71 Ceeraz S. Eszterhas S.K. Sergent P.A. Armstrong D.A. Ashare A. Broughton T. Wang L. Pechenick D. Burns C.M. Noelle R.J. Vincenti M.P. Fava R.A. VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes Arthritis Res. Ther. 19 2017 270 10.1186/s13075-017-1474-y 29216931
72 Darling V.R. Hauke R.J. Tarantolo S. Agrawal D.K. Immunological effects and therapeutic role of C5a in cancer Expet Rev. Clin. Immunol. 11 2015 255 10.1586/1744666X.2015.983081
73 Reis E.S. Mastellos D.C. Ricklin D. Mantovani A. Lambris J.D. Complement in cancer: untangling an intricate relationship Nat. Rev. Immunol. 18 2018 5 18 10.1038/nri.2017.97 28920587
74 The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells Cancer Lett. 549 2022 215900 10.1016/j.canlet.2022.215900
75 Markiewski M.M. DeAngelis R.A. Benencia F. Ricklin-Lichtsteiner S.K. Koutoulaki A. Gerard C. Coukos G. Lambris J.D. Modulation of the antitumor immune response by complement Nat. Immunol. 9 2008 1225 1235 10.1038/ni.1655 18820683
76 Ortiz-Espinosa S. Morales X. Senent Y. Alignani D. Tavira B. Macaya I. Ruiz B. Moreno H. Remírez A. Sainz C. Rodriguez-Pena A. Oyarbide A. Ariz M. Andueza M.P. Valencia K. Teijeira A. Hoehlig K. Vater A. Rolfe B. Woodruff T.M. Lopez-Picazo J.M. Vicent S. Kochan G. Escors D. Gil-Bazo I. Perez-Gracia J.L. Montuenga L.M. Lambris J.D. Ortiz de Solorzano C. Lecanda F. Ajona D. Pio R. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis Cancer Lett. 529 2022 70 84 10.1016/j.canlet.2021.12.027 34971753
77 Markiewski M.M. DeAngelis R.A. Benencia F. Ricklin-Lichtsteiner S.K. Koutoulaki A. Gerard C. Coukos G. Lambris J.D. Modulation of the anti-tumor immune response by complement Nat. Immunol. 9 2008 1225 1235 10.1038/ni.1655 18820683
78 Zhang K. Zakeri A. Alban T. Dong J. Ta H.M. Zalavadia A.H. Branicky A. Zhao H. Juric I. Husich H. Parthasarathy P.B. Rupani A. Drazba J.A. Chakraborty A.A. Ching-Cheng Huang S. Chan T. Avril S. Wang L.L. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms Cell Rep. 43 2024 113661 10.1016/j.celrep.2023.113661
79 Gabrilovich D.I. Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174 10.1038/nri2506 19197294
80 Rodriguez P.C. Quiceno D.G. Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression Blood 109 2007 1568 1573 10.1182/blood-2006-06-031856 17023580
81 Rodriguez PC Zea AH Culotta KS Zabaleta J Ochoa JB Ochoa AC Regulation of T cell receptor CD3zeta chain expression by L-arginine J Biol Chem.277 2002 10.1074/jbc.M110675200 21123-9
82 Harari O. Liao J.K. Inhibition of MHC II gene transcription by nitric oxide and antioxidants Curr. Pharmaceut. Des. 10 2004 893 898 10.2174/1381612043452893
83 Xu J. Luo Y. Yuan C. Han L. Wu Q. Xu L. Gao Y. Sun Y. Ma S. Tang G. Li S. Sun W. Gong Y. Xie C. Downregulation of nitric oxide collaborated with radiotherapy to promote anti-tumor immune response via inducing CD8+ T cell infiltration Int. J. Biol. Sci. 16 2020 1563 1574 10.7150/ijbs.41653 32226302
84 Bingisser R.M. Tilbrook P.A. Holt P.G. Kees U.R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway J. Immunol. 160 1998 5729 5734 9637481
85 Yu C. Fitzpatrick A. Cong D. Yao C. Yoo J. Turnbull A. Schwarze J. Norval M. Howie S.E.M. Weller R.B. Astier A.L. Nitric oxide induces human CLA+CD25+Foxp3+ regulatory T cells with skin-homing potential J. Allergy Clin. Immunol. 140 2017 1441 1444.e6 10.1016/j.jaci.2017.05.023 28601680
86 Cartwright ANR Suo S Badrinath S Kumar S Melms J Luoma A Bagati A Saadatpour A Izar B Yuan GC Wucherpfennig KW Immunosuppressive Myeloid Cells Induce Nitric Oxide-Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells Cancer Immunol Res 9 2021 470 485 10.1158/2326-6066 33514509
87 Le Mercier I. Chen W. Lines J.L. Day M. Li J. Sergent P. Noelle R.J. Wang L. VISTA regulates the development of protective antitumor immunity Cancer Res. 74 2014 1933 1944 10.1158/0008-5472.CAN-13-1506 24691994
88 Wakiyama H. Furusawa A. Okada R. Inagaki F. Kato T. Furumoto H. Fukushima H. Okuyama S. Choyke P.L. Kobayashi H. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers Cancer Immunol. Immunother. 2022 10.1007/s00262-022-03205-5
89 Boyd-kirkup, Jerome Douglas (Singapore, SG), Ingram, Piers (Singapore, SG), Thakkar, Dipti (Singapore, SG), Wu, Zhihao (Singapore, SG), Paszkiewicz, Konrad (Singapore, SG), Sancenon, Vicente (Singapore, SG), Guan, Siyu (Singapore, SG) 2019 VISTA ANTIGEN-BINDING MOLECULES United States Hummingbird Bioscience Pte. Ltd. (Singapore, SG),Hummingbird Bioscience Holdings Pte. Ltd. (Singapore, SG) 20190300610 https://www.freepatentsonline.com/y2019/0300610.html.
90 Liu J. Lin W.-P. Xiao Y. Yang Q.-C. Bushabu Fidele N. Yu H.-J. Sun Z.-J. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma Int. Immunopharm. 125 2023 111128 10.1016/j.intimp.2023.111128
91 Molloy, Michael (Enfield, NH, US), Guo, Yalin (Hanover, NH, US), Rothstein, Jay (Norwich, VT, US), Rosenzweig, Michael (Boston, MA, US) 2016 IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS United States IMMUNEXT, INC. (LEBANON, NH, US) 20160159927 https://www.freepatentsonline.com/y2016/0159927.html.
92 Zheng S. Zhang K. Zhang X. Xiao Y. Wang T. Jiang S. Development of inhibitors targeting the V-domain Ig suppressor of T cell activation signal pathway J. Med. Chem. 13 2022
93 Curis Inc Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies, clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT04475523 2022
94 Guillaudeux T. Iadonato S. Tarcha E. Philips C. 268 KVA 12.1 a novel fully human anti-VISTA antibody: clinical trial design in monotherapy and in combination with an anti-PD1 antibody J Immunother Cancer 9 2021 A291 10.1136/jitc-2021-SITC2021.268 A291
95 First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04564417?term=NCT04564417&draw=2&rank=1 (accessed October 16, 2022).
96 Cheon Ho Park Sang Soon Byun Jin Yong An Han Hyerim Weon Sup Lee; Abstract 5557: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Cancer Res. 82 2022 5557 10.1158/1538-7445.AM2022-5557
97 R. Pierce, SNS-101, A Unique Tumor-Selective Anti-VISTA Monoclonal Antibody with a Novel Mechanism of Action, (n.d.) 24.
98 Hu, Wenqi (Las Vegas, NV, US), Li, Jiangmei (Beijing, CN), Li, Feng (Beijing, CN) 2020 Antibodies binding VISTA and uses thereof United States Beijing Mabworks Biotech Co.Ltd (Beijing, CN) 10577424 https://www.freepatentsonline.com/10577424.html.
99 Vanhaver C. van der Bruggen P. Bruger A.M. MDSC in mice and men: mechanisms of immunosuppression in cancer J. Clin. Med. 10 2021 2872 10.3390/jcm10132872 34203451
100 Law A.M.K. Valdes-Mora F. Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer Cells. 9 2020 561 10.3390/cells9030561 32121014
101 Fědorová L. Pilátová K. Selingerová I. Bencsiková B. Budinská E. Zwinsová B. Brychtová V. Langrová M. Šefr R. Valík D. Zdražilová Dubská L. Circulating myeloid-derived suppressor cell subsets in patients with colorectal cancer - exploratory analysis of their biomarker potential Klin. Onkol. 31 2018 88 92 31023030
102 Saleh R. Sasidharan Nair V. Al-Dhaheri M. Khawar M. Abu Nada M. Alajez N.M. Elkord E. RNA-seq analysis of colorectal tumor-infiltrating myeloid-derived suppressor cell subsets revealed gene signatures of poor prognosis Front. Oncol. 10 2020 604906 10.3389/fonc.2020.604906
103 Roussel M. Ferrell P.B. Greenplate A.R. Lhomme F. Le Gallou S. Diggins K.E. Johnson D.B. Irish J.M. Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow J. Leukoc. Biol. 102 2017 437 447 10.1189/jlb.5MA1116-457R 28400539
104 Feng P.-H. Lee K.-Y. Chang Y.-L. Chan Y.-F. Kuo L.-W. Lin T.-Y. Chung F.-T. Kuo C.-S. Yu C.-T. Lin S.-M. Wang C.-H. Chou C.-L. Huang C.-D. Kuo H.-P. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer Am. J. Respir. Crit. Care Med. 186 2012 1025 1036 10.1164/rccm.201204-0636OC 22955317
105 Vetsika E.-K. Koinis F. Gioulbasani M. Aggouraki D. Koutoulaki A. Skalidaki E. Mavroudis D. Georgoulias V. Kotsakis A. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients J Immunol Res 2014 2014 659294 10.1155/2014/659294
106 Nagaraj S. Gupta K. Pisarev V. Kinarsky L. Sherman S. Kang L. Herber D.L. Schneck J. Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer Nat. Med. 13 2007 828 835 10.1038/nm1609 17603493
107 Ugolini A. Tyurin V.A. Tyurina Y.Y. Tcyganov E.N. Donthireddy L. Kagan V.E. Gabrilovich D.I. Veglia F. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer JCI Insight 5 2020 138581 10.1172/jci.insight.138581
108 Veglia F. Sanseviero E. Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity Nat. Rev. Immunol. 21 2021 485 498 10.1038/s41577-020-00490-y 33526920
109 Corzo C.A. Condamine T. Lu L. Cotter M.J. Youn J.-I. Cheng P. Cho H.-I. Celis E. Quiceno D.G. Padhya T. McCaffrey T.V. McCaffrey J.C. Gabrilovich D.I. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment J. Exp. Med. 207 2010 2439 2453 10.1084/jem.20100587 20876310
110 Dolcetti L. Peranzoni E. Ugel S. Marigo I. Fernandez Gomez A. Mesa C. Geilich M. Winkels G. Traggiai E. Casati A. Grassi F. Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF Eur. J. Immunol. 40 2010 22 35 10.1002/eji.200939903 19941314
111 Maenhout S.K. Van Lint S. Emeagi P.U. Thielemans K. Aerts J.L. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts Int. J. Cancer 134 2014 1077 1090 10.1002/ijc.28449 23983191
112 Greene S. Robbins Y. Mydlarz W.K. Huynh A.P. Schmitt N.C. Friedman J. Horn L.A. Palena C. Schlom J. Maeda D.Y. Zebala J.A. Clavijo P.E. Allen C. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models Clin. Cancer Res. 26 2020 1420 1431 10.1158/1078-0432.CCR-19-2625 31848188
113 Toor S.M. Syed Khaja A.S. El Salhat H. Faour I. Kanbar J. Quadri A.A. Albashir M. Elkord E. Myeloid cells in circulation and tumor microenvironment of breast cancer patients Cancer Immunol. Immunother. 66 2017 753 764 10.1007/s00262-017-1977-z 28283696
114 F V. A H. H D. E S. A D.L. T. E, K. A, M. C, N. B, M. G, P. J V B. P W. D S. Ma S. S S. Eb E. R C. A L. Y N. Di G. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice J. Exp. Med. 218 2021 10.1084/jem.20201803
115 Tcyganov EN Hanabuchi S Hashimoto A Campbell D Kar G Slidel TW Cayatte C Landry A Pilataxi F Hayes S Dougherty B Hicks KC Mulgrew K Tang CA Hu CA Guo W Grivennikov S Ali MA Beltra JC Wherry EJ Nefedova Y Gabrilovich DI Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer J Clin Invest 16 2021 e145971 10.1172/JCI145971
116 Cruzalegui F. Loukili N. Delfour O. Boute N. Thuilliez C. Champion T. Malissard M. Launay P. Chetaille E. Passioukov A. Corvaïa N. Ferré P. Abstract 3372: VISTA interaction with PSGL1, a likely VISTA receptor in tumors, is effectively disrupted by K0401-020 anti-VISTA antibody Cancer Res. 80 2020 3372 10.1158/1538-7445.AM2020-3372 32561532
117 M. Zauderer, J. Brody, T. Marron, S. Pacey, R. Martell, H. Wang, J. Spicer, First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101, (n.d.).
118 Zong L. Mo S. Sun Z. Lu Z. Yu S. Chen J. Xiang Y. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer Mod. Pathol. 35 2022 266 273 10.1038/s41379-021-00901-y 34493823
119 Guillermo Garcia-Manero, Uwe Platzbecker, Stefano R. Tarantolo, Stefanie Gropper, Chetasi Talati, Katharina S. Götze, James Dugan, Eric S. Winer, Elizabeth Martinez, Christopher Lieberman, Reinhard von Roemeling, A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Blood, 136 (2020) 16, 10.1182/blood-2020-140889.
120 Sen S, Call J, Papadopoulos K, et al1532â€…A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11 (2023) 1532;doi: 10.1136/jitc-2023-SITC2023.
121 Sasikumar P.G. Naremaddepalli S.S. Ramachandra R.K. Gowda N. Yerramsetti M.R. Bandireddy S.R. Adurthi S. Mani J. Nair R. Dhudashia A.A. Dodheri S.S. Gowda N.M. Ramachandra M. Abstract B006: functional antagonism of VSIG8-mediated immune suppression by oral VISTA agents Mol. Cancer Therapeut. 17 2018 B006 10.1158/1535-7163.TARG-17-B006
122 Gabr MT Gambhir SS Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA) J Am Chem Soc.142 2020 16194 16198 10.1021/jacs.0c07276
123 Karin N. The development and homing of myeloid-derived suppressor cells: from a two-stage model to a multistep narrative Front. Immunol. 11 2020 https://www.frontiersin.org/articles/10.3389/fimmu.2020.557586
124 Noubissi Nzeteu G.A. Schlichtner S. David S. Ruppenstein A. Fasler-Kan E. Raap U. Sumbayev V.V. Gibbs B.F. Meyer N.H. Macrophage differentiation and polarization regulate the release of the immune checkpoint protein V-domain Ig suppressor of T cell activation Front. Immunol. 13 2022 10.3389/fimmu.2022.837097
125 Nishizaki D. Kurzrock R. Miyashita H. Adashek J.J. Lee S. Nikanjam M. Eskander R.N. Patel H. Botta G.P. Nesline M.K. Pabla S. Conroy J.M. DePietro P. Sicklick J.K. Kato S. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers ESMO Open 9 2024 102942 10.1016/j.esmoop.2024.102942
126 Zong L. Mo S. Sun Z. Lu Z. Yu S. Chen J. Xiang Y. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer Mod. Pathol. 35 2022 266 273 10.1038/s41379-021-00901-y 34493823
127 Lin Y Choukrani G Dubbel L Rockstein L Freile JA Qi Y Wiersma V Zhang H Koch KW Ammatuna E Schuringa JJ van Meerten T Huls G Bremer E VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses Exp Hematol Oncol 13 2024 35 10.1186/s40164-024-00501-x 38553748
128 Tesi R.J. MDSC; the most important cell you have never heard of Trends Pharmacol. Sci. 40 2019 4 7 10.1016/j.tips.2018.10.008 30527590
